Soft tissue sarcomas: radiation as a therapeutic option

Area of Science:

• Oncology
• Radiation Oncology
• Surgical Oncology

Background:

• Primary soft tissue sarcomas require effective management strategies balancing tumor control and treatment-related morbidity.
• Current standard treatment involves conservative surgery and moderate-dose radiation therapy (50-60 Gy).
• Soft tissue sarcoma cells are not inherently radioresistant, supporting the efficacy of radiation-based treatments.

Purpose of the Study:

• To assess the effectiveness of various treatment modalities for primary soft tissue sarcomas.
• To compare local control rates and functional/cosmetic outcomes of different therapeutic approaches.
• To investigate the role of neoadjuvant chemotherapy and radiation in sarcoma management.

Main Methods:

• Review of existing data on surgical resection, radiation therapy (pre- and post-operative), and chemotherapy.
• Evaluation of radiation doses (50-75 Gy) and their impact on local control.
• Analysis of ongoing trials, including a Phase II trial of MAID chemotherapy and preoperative radiation.

Main Results:

• Combined modality treatment (surgery and radiation) achieves high local control rates (85-90%) with preserved function and cosmesis.
• Radiation therapy alone (around 75 Gy) is effective for small sarcomas (< or = 60 ml) when surgery is not feasible.
• Adjuvant chemotherapy has not shown a clear benefit, but neoadjuvant chemotherapy (e.g., MAID) shows promising results in ongoing trials.

Conclusions:

• Combined modality treatment, particularly preoperative radiation followed by surgery, is a preferred approach for T2, Grade II-III soft tissue sarcomas.
• Radiation therapy alone is a viable option for selected patients.
• Further research is needed to evaluate functional and cosmetic outcomes across diverse treatment strategies.